본문 바로가기
KERD
논문KCI 등재

Drug-Induced Parkinsonism

정선주|신혜원
대한신경과학회 (Korean Neurological Association)|2012.03|Journal of Clinical Neurology|제8권 제1호|pp. 15-21

2

조회

0

다운로드

19

인용

0

참고문헌

키워드

Parkinsonismdopamine transporter imagingtreatment.dopamine receptor blocking agentsclinical manifestations

초록

Drug-induced parkinsonism (DIP) is the second-most-common etiology of parkinsonism in the elderly after Parkinson’s disease (PD). Many patients with DIP may be misdiagnosed with PD because the clinical features of these two conditions are indistinguishable. Moreover, neurological deficits in patients with DIP may be severe enough to affect daily activities and may persist for long periods of time after the cessation of drug taking. In addition to typical antipsychotics, DIP may be caused by gastrointestinal prokinetics, calcium channel blockers, atypical antipsychotics, and antiepileptic drugs. The clinical manifestations of DIP are classically described as bilateral and symmetric parkinsonism without tremor at rest. However, about half of DIP patients show asymmetrical parkinsonism and tremor at rest, making it difficult to differentiate DIP from PD. The pathophysiology of DIP is related to drug-induced changes in the basal ganglia motor circuit secondary to dopaminergic receptor blockade. Since these effects are limited to postsynaptic dopaminergic receptors, it is expected that presynaptic dopaminergic neurons in the striatum will be intact. Dopamine transporter (DAT) imaging is useful for diagnosing presynaptic parkinsonism. DAT uptake in the striatum is significantly decreased even in the early stage of PD, and this characteristic may help in differentiating PD from DIP. DIP may have a significant and longstanding effect on patients’daily lives, and so physicians should be cautious when prescribing dopaminergic receptor blockers and should monitor patients’ neurological signs, especially for parkinsonism and other movement disorders.

Abstract

Drug-induced parkinsonism (DIP) is the second-most-common etiology of parkinsonism in the elderly after Parkinson’s disease (PD). Many patients with DIP may be misdiagnosed with PD because the clinical features of these two conditions are indistinguishable. Moreover, neurological deficits in patients with DIP may be severe enough to affect daily activities and may persist for long periods of time after the cessation of drug taking. In addition to typical antipsychotics, DIP may be caused by gastrointestinal prokinetics, calcium channel blockers, atypical antipsychotics, and antiepileptic drugs. The clinical manifestations of DIP are classically described as bilateral and symmetric parkinsonism without tremor at rest. However, about half of DIP patients show asymmetrical parkinsonism and tremor at rest, making it difficult to differentiate DIP from PD. The pathophysiology of DIP is related to drug-induced changes in the basal ganglia motor circuit secondary to dopaminergic receptor blockade. Since these effects are limited to postsynaptic dopaminergic receptors, it is expected that presynaptic dopaminergic neurons in the striatum will be intact. Dopamine transporter (DAT) imaging is useful for diagnosing presynaptic parkinsonism. DAT uptake in the striatum is significantly decreased even in the early stage of PD, and this characteristic may help in differentiating PD from DIP. DIP may have a significant and longstanding effect on patients’daily lives, and so physicians should be cautious when prescribing dopaminergic receptor blockers and should monitor patients’ neurological signs, especially for parkinsonism and other movement disorders.

참고문헌 (72)

  1. Miller LG, "Neurologic approach to drug-induced movement disorders: a study of 125 patients", South Med J, 83, pp.525~532 (1990)
  2. Montastruc JL, "Drug-induced parkinsonism: a review", Fundam Clin Pharmacol, 8, pp.293~306 (1994)
  3. Sethi KD, "Movement disorders induced by dopamine blocking agents", Semin Neurol, 21, pp.59~68 (2001)
  4. Esper CD, "Failure of recognition of drug-induced parkinsonism in the elderly", Mov Disord, 23, pp.401~404 (2008)
  5. Kägi G, "The role of DAT-SPECT in movement disorders", J Neurol Neurosurg Psychiatry, 81, pp.5~12 (2010)
  6. Scherfler C, "Role of DAT-SPECT in the diagnostic work up of parkinsonism", Mov Disord, 22, pp.1229~1238 (2007)
  7. Hall RA, "Neurotoxic reactions resulting from chlorpromazine administration", J Am Med Assoc, 161, pp.214~218 (1956)
  8. Benito-León J, "Neurological Disorders in Central Spain (NEDICES) Study Group. Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain", Mov Disord, 18, pp.267~274 (2003)
  9. Wenning GK, "Prevalence of movement disorders in men and women aged 50-89 years (Bruneck Study cohort): a population-based study", Lancet Neurol, 4, pp.815~820 (2005)
  10. Barbosa MT, "Parkinsonism and Parkinson’s disease in the elderly: a community-based survey in Brazil (the Bambuí study)", Mov Disord, 21, pp.800~808 (2006)
  11. Avorn J, "Neuroleptic drug exposure and treatment of parkinsonism in the elderly: a case-control study", Am J Med, 99, pp.48~54 (1995)
  12. Susatia F, "Drug-induced parkinsonism", Curr Treat Options Neurol, 11, pp.162~169 (2009)
  13. Thanvi B, "Drug induced parkinsonism: a common cause of parkinsonism in older people", Postgrad Med J, 85, pp.322~326 (2009)
  14. Volkow ND, "Dopamine transporters decrease with age", J Nucl Med, 37, pp.554~559 (1996)
  15. Stephen PJ, "Drug-induced parkinsonism in the elderly", Lancet, 2, pp.1082~1083 (1984)
  16. Hardie RJ, "Neuroleptic-induced Parkinson’s syndrome: clinical features and results of treatment with levodopa", J Neurol Neurosurg Psychiatry, 51, pp.850~854 (1988)
  17. Miller LG, "Metoclopramide-induced movement disorders. Clinical findings with a review of the literature", Arch Intern Med, 149, pp.2486~2492 (1989)
  18. Bedard P, "Oestrogens and extrapyramidal system", Lancet, 2, pp.1367~1368 (1977)
  19. Metzer WS, "HLA antigens in drug-induced parkinsonism", Mov Disord, 4, pp.121~128 (1989)
  20. Liou YJ, "Association analysis of polymorphisms in the N-methyl-D-aspartate (NMDA) receptor subunit 2B (GRIN2B) gene and tardive dyskinesia in schizophrenia", Psychiatry Res, 153, pp.271~275 (2007)
  21. Inada T, "Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia", Pharmacogenet Genomics, 18, pp.317~323 (2008)
  22. Shanon J, "An interesting reaction to a tranquilizer: tonic seizures with perphenazine (trilafon)", Am J Psychiatry, 114, pp.556~ (1957)
  23. Christian CD, "Severe motility disturbance after small doses of prochlorperazine", N Engl J Med, 259, pp.828~830 (1958)
  24. Janno S, "Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients", Am J Psychiatry, 161, pp.160~163 (2004)
  25. Ossowska K, "Neuronal basis of neuroleptic-induced extrapyramidal side effects", Pol J Pharmacol, 54, pp.299~312 (2002)
  26. Tarsy D, "Effects of newer antipsychotics on extrapyramidal function", CNS Drugs, 16, pp.23~45 (2002)
  27. Kuroki T, "Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis", Prog Brain Res, 172, pp.199~212 (2008)
  28. Kapur S, "Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis", Am J Psychiatry, 158, pp.360~369 (2001)
  29. Stahl SM, "“Hit-and-Run” actions at dopamine receptors, part 2: illustrating fast dissociation from dopamine receptors that typifies atypical antipsychotics", J Clin Psychiatry, 62, pp.747~748 (2001)
  30. "Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. The Parkinson Study Group", N Engl J Med, 340, pp.757~763 (1999)
  31. Schotte A, "Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding", Psychopharmacology (Berl), 124, pp.57~73 (1996)
  32. Gómez JC, "The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia", J Clin Psychiatry, 61, pp.335~343 (2000)
  33. Rabey JM, "Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration", Mov Disord, 22, pp.313~318 (2007)
  34. Juncos JL, "Quetiapine improves psychotic symptoms and cognition in Parkinson’s disease", Mov Disord, 19, pp.29~35 (2004)
  35. Wickremaratchi M, "Aripiprazole associated with severe exacerbation of Parkinson’s disease", Mov Disord, 21, pp.1538~1539 (2006)
  36. Sharma A, "Aripiprazole-induced parkinsonism", Int Clin Psychopharmacol, 21, pp.127~129 (2006)
  37. Tonini M, "Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics", Aliment Pharmacol Ther, 19, pp.379~390 (2004)
  38. Kenney C, "Metoclopramide, an increasingly recognized cause of tardive dyskinesia", J Clin Pharmacol, 48, pp.379~384 (2008)
  39. "Parkinsonism: an under-recognised complication of metoclopramide use", Ceylon Med J, 41, pp.125~ (1996)
  40. Sethi KD, "Metoclopramide-induced parkinsonism", South Med J, 82, pp.1581~1582 (1989)
  41. Shin HW, "Levosulpiride-induced movement disorders", Mov Disord, 24, pp.2249~2253 (2009)
  42. Madej TH, "Domperidone--an acute dystonic reaction", Anaesthesia, 40, pp.202~ (1985)
  43. Sørensen PS, "A placebo-controlled, double-blind, cross-over trial of flunarizine in common migraine", Cephalalgia, 6, pp.7~14 (1986)
  44. Garcı´a-Ruiz PJ, "Calcium channel blocker-induced parkinsonism: clinical features and comparisons with Parkinson’s", Parkinsonism Relat Disord, 4, pp.211~214 (1998)
  45. Martí-Massó JF, "Cinnarizine-induced parkinsonism: ten years", Mov Disord, 13, pp.453~456 (1998)
  46. Negrotti A, "A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism", Mov Disord, 12, pp.107~110 (1997)
  47. Takada M, "Flunarizine induces a transient loss of tyrosine hydroxylase immunoreactivity in nigrostriatal neurons", Brain Res, 590, pp.311~315 (1992)
  48. Onofrj M, "Reversible parkinsonism induced by prolonged treatment with valproate", J Neurol, 245, pp.794~796 (1998)
  49. Easterford K, "Reversible parkinsonism with normal beta-CIT-SPECT in patients exposed to sodium valproate", Neurology, 62, pp.1435~1437 (2004)
  50. Jamora D, "Valproate-induced Parkinsonism in epilepsy patients", Mov Disord, 22, pp.130~133 (2007)
  51. Reches A, "Parkinsonism due to lithium carbonate poisoning", Arch Neurol, 38, pp.471~ (1981)
  52. Holroyd S, "Disabling parkinsonism due to lithium: a case report", J Geriatr Psychiatry Neurol, 8, pp.118~119 (1995)
  53. FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism, "J Neurol", 2009, 910~915
  54. Hassin-Baer S, "Clinical characteristics of neuroleptic-induced parkinsonism", J Neural Transm, 108, pp.1299~1308 (2001)
  55. Jaber M, "Dopamine receptors and brain function", Neuropharmacology, 35, pp.1503~1519 (1996)
  56. Farde L, "Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects", Arch Gen Psychiatry, 49, pp.538~544 (1992)
  57. Gunne LM, "An animal model for coexisting tardive dyskinesia and tardive parkinsonism: a glutamate hypothesis for tardive dyskinesia", Clin Neuropharmacol, 16, pp.90~95 (1993)
  58. Gershanik OS, "Drug-induced parkinsonism in the aged. Recognition and prevention", Drugs Aging, 5, pp.127~132 (1994)
  59. Jiménez-Jiménez FJ, "Drug-induced parkinsonism in a movement disorders unit: a four-year survey", Parkinsonism Relat Disord, 2, pp.145~149 (1996)
  60. Davis MR, "Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT", J Nucl Med, 44, pp.855~861 (2003)
  61. Varrone A, "Molecular imaging of the dopamine transporter", J Nucl Med, 51, pp.1331~1334 (2010)
  62. Diaz-Corrales FJ, "Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson’s disease", Eur J Nucl Med Mol Imaging, 37, pp.556~564 (2010)
  63. -FP, "CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson’s disease", Mov Disord, 21, pp.510~514 (2006)
  64. FP-CIT SPET imaging in drug-induced Parkinsonism, "Mov Disord", 2008, 1825~1829
  65. Poewe W, "Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice", Mov Disord, 18(7), pp.S16~S21 (2003)
  66. FP-CIT SPECT, "Schizophr Res", 2001, 59~67
  67. Tolosa E, "DAT imaging in drug-induced and psychogenic parkinsonism", Mov Disord, 18(7), pp.S28~S33 (2003)
  68. Fann WE, "Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism", Am J Psychiatry, 133, pp.940~943 (1976)
  69. Jankovic J, "Tardive syndromes and other drug-induced movement disorders", Clin Neuropharmacol, 18, pp.197~214 (1995)
  70. Rajput AH, "Reversible drug-induced parkinsonism. Clinicopathologic study of two cases", Arch Neurol, 39, pp.644~646 (1982)
  71. Bishnoi M, "Protective effect of adenosine reuptake inhibitors in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes", Pharmacology, 79, pp.171~183 (2007)
  72. Tsai G, "Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia", Am J Psychiatry, 155, pp.1207~1213 (1998)

관련 논문AI추천

Cardiovascular Autonomic Dysfunction in Patients with Drug-Induced Parkinsonism김중석, 류동우, 박성진, 소정민, 오주희, 이광수, 이양현, 임진희, 전기평, 호성희대한신경과학회 · Journal of Clinical Neurology2017 · 제13권 제1호Clinical Aspects of the Differential Diagnosis of Parkinson’s Disease and Parkinsonism신혜원, 윤영철, 홍상욱대한신경과학회 · Journal of Clinical Neurology2022 · 제18권 제3호Trends in the Prevalence of Drug-Induced Parkinsonism in Korea김윤중, 김중석, 마효일, 백종삼, 변지혜, 장선미, 조혜민연세대학교의과대학 · Yonsei Medical Journal2019 · 제60권 제8호Drug Induced Parkinsonism Caused by the Concurrent Use of Donepezil and Risperidone in a Patient With Traumatic Brain Injuries강시현, 김돈규대한재활의학회 · Annals of Rehabilitation Medicine2013 · 제37권 제1호Quetiapine: The Possibility of Quetiapine as a Cause of Neuroleptic Hypersensitivity in Dementia with Lewy Bodies신동익, 한현정, Go Un Kim, Hyung Woo Shin, Jong-Ho Park, Sang Joon An대한치매학회 · Dementia and Neurocognitive Disorders(대한치매학회지)2009 · 제8권 제2호Recent Advances in the Pharmacology of Tardive DyskinesiaStanley N. Caroff대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2020 · 제18권 제4호

이 간행물의 다른 논문 (11건)

Pitfalls in Using Electrophysiological Studies to Diagnose Neuromuscular Disorders김병조, Charles S. Cho, 구용서pp. 1-14Clinical Utility of Interictal High-Frequency Oscillations Recorded with Subdural Macroelectrodes in Partial Epilepsydaelimkoo, 홍승봉, 홍승철, 민병훈, 주은연, Jounhong Ryan Chopp. 22-34Theta Oscillation Related to the Auditory Discrimination Process in Mismatch Negativity: Oddball versus Control Paradigm임창환, 이관택, 고덕원, 권소영, 김경환, 정기영pp. 35-42Medial Temporal Atrophy and Memory Dysfunction in Poststroke Cognitive Impairment-No Dementia한문구, 이준영, 강연욱, 유경호, 이병철, 오미영, 김상윤, 이지성, 윤병우, 배희준, 김범준pp. 43-50Sleep-Related Falling Out of Bed in Parkinson’s Diseasedmwallace, sshafazand, dzcarvalho, fbnahab, csengun, arussell, hpmoore, csingerpp. 51-57
원문 보기